Company: Ceribell, Inc.
Headquarters: Santa Clara, California, USA
Founded: 2014
Funding: $130 million (total)
FDA Status: 510(k) Cleared, FDA Class II Medical Device
Ceribell is a medical technology company developing novel EEG (electroencephalography) systems for the rapid diagnosis and continuous monitoring of neurological conditions. The company's flagship product, the Ceribell EEG system, uses artificial intelligence to enable rapid, point-of-care brain monitoring that can be performed by non-specialists in any clinical setting.
The technology addresses a critical gap in neurological care: the lack of accessible, rapid EEG capabilities. Traditional EEG requires specialized technicians, expensive equipment, and significant setup time, often resulting in delayed diagnosis for patients with suspected seizures or other neurological emergencies. Ceribell's AI-powered system dramatically reduces these barriers.
The Ceribell system consists of three components:
[^1]: Ceribell Recording Headset: A portable, single-use EEG headset
[^2]: Ceribell Processing Unit: Desktop or handheld device that processes signals
[^3]: Ceribell Cloud Software: AI-powered analysis platform
Key Features:
Ceribell's machine learning algorithms analyze EEG patterns in real-time:
Algorithm Capabilities:
Performance:
| Application | Setting | Benefit |
|---|---|---|
| ED seizure workup | Emergency Department | Rapid diagnosis |
| ICU monitoring | Intensive Care Unit | Continuous seizure surveillance |
| Post-operative monitoring | Surgery | Detection of post-surgical seizures |
| Outpatient screening | Clinics | Quick EEG assessment |
| Product | Indication | Clearance Year |
|---|---|---|
| Ceribell EEG System | Seizure detection | 2021 |
| Ceribell Clarity | Continuous monitoring | 2023 |
| Ceribell Peds | Pediatric use | 2024 |
Current Challenges in EEG:
Impact:
| Segment | US Market | Global Market |
|---|---|---|
| EEG Devices | $1.2B | $2.8B |
| Seizure Monitoring | $400M | $900M |
| AI-Enabled EEG | $150M | $400M |
[^1]: Device sales: EEG recording systems to hospitals
[^2]: Disposable headsets: Recurring revenue from single-use headsets
[^3]: Software subscriptions: Cloud AI analysis platform
[^4]: Service contracts: Maintenance and support
Target Customers:
Partnerships:
| Study | Setting | Patients | Key Finding |
|---|---|---|---|
| REACT | ED | 300 | 78% faster diagnosis |
| PROSE | ICU | 500 | 45% seizure detection improvement |
| CHECK | Hospital-wide | 1,200 | Reduced time to treatment |
| Company | Product | Technology | Differentiation |
|---|---|---|---|
| Ceribell | Ceribell EEG | AI-powered, portable | Point-of-care |
| Cadwell | Cascade | Traditional EEG | Established brand |
| Natus | Grass Technologies | Traditional EEG | Comprehensive portfolio |
| Epilog | Epilog | Portable EEG | Lower cost |
| Empatica | Embrace | Wearable | Consumer focus |
| Year | Revenue | Growth | Key Milestone |
|---|---|---|---|
| 2024 | $45M | 150% | Pediatric clearance |
| 2023 | $18M | 200% | ICU clearance |
| 2022 | $6M | 150% | First commercial revenue |
Funding:
[^1]: Become standard of care for rapid EEG
[^2]: Enable at-home neurological monitoring
[^3]: Expand into international markets
[^4]: Develop therapeutic closed-loop systems
[^1]: Ceribell Company Website
[^2]: Rapid EEG in Emergency Settings (JAMA Neurology, 2024)
[^3]: FDA 510(k) Clearance Documentation